NDAINTRAVENOUSSOLUTIONPriority Review
Approved
May 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Clinical Trials (2)
A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
Started Nov 2024
[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
Started Jun 2019
Loss of Exclusivity
LOE Date
Apr 23, 2042
196 months away
Patent Expiry
Apr 23, 2042